Showing 3071-3080 of 5621 results for "".
- Alcon Reinforces Strength of Ophthalmology Portfolio With Surgical Device Scientific Presence at ASCRShttps://modernod.com/news/alcon-reinforces-strength-of-ophthalmology-portfolio-with-surgical-device-scientific-presence-at-ascrs/2479398/Alcon will present a breadth of data during the American Society of Cataract and Refractive Surgery (ASCRS) 2021 annual meeting, taking place July 23-27 in Las Vegas. More than 60 abstracts featuring Alcon ophthalmic products and equipment will be presented. The full abstract book, registration l
- Eyenuk Announces $6.2 Million Financing to Accelerate Adoption of FDA-Cleared AI Technology for Detection of Diabetic Retinopathyhttps://modernod.com/news/eyenuk-announces-6-2-million-financing-to-accelerate-adoption-of-fda-cleared-ai-technology-for-detection-of-diabetic-retinopathy/2479388/Eyenuk announced that it has completed a financing round of $6.2 million to accelerate commercialization of the EyeArt AI System, which received FDA clearance in 2020 and is being reimbursed by Medicare and other payo
- AMA Assigns CPT Code to Software Designed to Treat Adult Amblyopia (Lazy Eye)https://modernod.com/news/ama-assigns-cpt-code-to-software-designed-to-treat-adult-amblyopia-lazy-eye/2479361/RevitalVision announced that its standalone therapeutic vision training software, the only FDA-approved product for market, and clinically proven to improve vision in adult amblyopia (age 9-plus), received a unique Current Procedural Terminology (CPT) reimbursement code from the American Medical
- Sight Sciences Pitches $150M IPO for Its Glaucoma, Dry Eye Deviceshttps://modernod.com/news/sight-sciences-pitches-150m-ipo-for-its-glaucoma-dry-eye-devices/2479355/Sight Sciences hopes to see its way to nearly a $1 billion valuation through a $150 million Nasdaq IPO, according to a Fierce Biotech report. By going public, the Menlo Par
- Pfizer Plans to Seek FDA Nod for COVID-19 Booster Next Month as Delta Spreadshttps://modernod.com/news/pfizer-plans-to-seek-fda-nod-for-covid-19-booster-next-month-as-delta-spreads/2479354/Pfizer’s chief scientific officer Mikael Dolsten indicated Thursday that the company plans to seek an FDA emergency-use authorization next month for a third dose of its COVID-19 vaccine BNT162b2, according to a FirstWord report. The mRNA-based vaccine, partnered with BioNTech, is cur
- Ocugen Climbs on Phase 3 COVID Vaccine Data, Hitting Back at Delta Varianthttps://modernod.com/news/ocugen-climbs-on-phase-3-covid-vaccine-data-hitting-back-at-delta-variant/2479348/After seeing its stock fall consistently over the past few months, Ocugen and partner Bharat Biotech have posted some encouraging data from their pandemic vaccine Covaxin, according to a FierceBiotech report. The latest look from its lat
- “Love Your Eyes” Theme of 2021 World Sight Dayhttps://modernod.com/news/love-your-eyes-theme-of-2021-world-sight-day/2479345/The International Agency for the Prevention of Blindness (IAPB) and its members are calling on everyone to focus on their eye health in a global campaign – #LoveYourEyes. The theme and materials are being launched on July 6 to mark 100 days to go until World Sight Day on October 14.
- EyePoint Pharmaceuticals Reports Positive 30-Day Safety Results for All Cohorts From DAVIO Trial of EYP-1901 for Wet AMDhttps://modernod.com/news/eyepoint-pharmaceuticals-reports-positive-30-day-safety-results-for-all-cohorts-from-the-davio-trial-of-eyp-1901-for-wet-amd/2479344/EyePoint Pharmaceuticals announced positive safety results from its phase 1 clinical trial of EYP-1901, a potential twice-yearly sustained delivery anti-VEGF treatment targeting wet age-related macular degeneration (AMD). All dose cohorts have reached at least 30-day post-dosing foll
- Nicox’s NCX 470 Demonstrates Significant Intraocular Pressure Lowering in Dolomites Phase 2 Glaucoma Trialhttps://modernod.com/news/nicoxs-ncx-470-demonstrates-significant-intraocular-pressure-lowering-in-dolomites-phase-2-glaucoma-trial/2479333/Nicox presented results from the Dolomites phase 2 clinical trial showing that NCX 470, a novel nitric oxide (NO)-donating prostaglandin analog (PGA), produced significantly greater IOP lowering effects in glaucoma patients compared with the current standard of care, latanoprost. In Dolom
- PYC Therapeutics Announces Preclinical Results Demonstrating VP-002 Program’s Potential as the First Disease Modifying Therapy for Autosomal Dominant Optic Atrophyhttps://modernod.com/news/pyc-therapeutics-announces-comprehensive-preclinical-results-demonstrating-vp-002-programs-potential-as-the-first-disease-modifying-therapy-for-autosomal-dominant-optic-atrophy/2479330/PYC Therapeutics released a summary of preclinical findings supporting the potential of PYC’s VP-002 program as the first disease-modifying therapy for patients suffering from Autosomal Dominant Optic Atrophy (ADOA). PYC’s PPMO technology used in the VP-002 program significantly increases levels